In addition, based on mouse models, CDKN2A could inhibit p53R172H-induced metastasis in HNSCC, and patients with HNSCC with both high-risk p53 mutations and pure CDKN2A deletions had the worst clinical outcomes (Li et al., 2016). This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.